Mushrooms distributed nationwide recalled for listeria risk: What to know
The Brief
Enoki mushrooms that were distributed across the United States have been recalled over possible listeria contamination.
The recall involves 200-gram packages of Enoki Mushrooms by Harvest NYC Inc of Brooklyn, New York.
Listeria infection can be fatal for young children, the elderly and immunocompromised people. It can also cause stillbirths and miscarriages in pregnant women.
Enoki mushrooms that were distributed across the United States have been recalled over possible listeria contamination.
The recall, published by the U.S. Food and Drug Administration on April 18, came after samples collected from a store in Buffalo, New York, revealed the presence of Listeria monocytogenes – the bacteria that causes Listeria infection.
Here's what to know:
What we know
Harvest NYC Inc of Brooklyn, New York, said the recall involves its 200-gram packages of Enoki Mushrooms – which are long, thin mushrooms typically used in soups, stir-frys, salads and other dishes.
The recalled mushrooms were distributed nationwide to retail stores, according to the FDA notice. The product comes in a 200-gram, green plastic package marked with UPC Barcode 6975730520101 on the back label, distributed by Hofood99 Inc., 21903 56th Ave, Oakland Gardens, NY 11364.
Why you should care
After contamination was discovered, a subsequent analysis by NYS Department of Agriculture and Markets Food Laboratory revealed the presence of Listeria monocytogenes in some of the 200-gram packages of Enoki Mushrooms, the notice said.
Listeria infection can cause fever, headache, stiffness, nausea, abdominal pain and diarrhea. In young children, the elderly and immunocompromised people, it can be fatal. It can also cause stillbirths and miscarriages in pregnant women.
Dig deeper
No illnesses have been reported to date in connection with this problem.
What you can do
Consumers who have purchased the recalled enoki mushrooms between Jan. 11 and Jan. 31, 2025, were urged to "destroy the products immediately or return them to the place of purchase for a full refund." Anyone with questions can contact the company at (718) 596-0777.
The Source
This story was written based on information provided by the U.S. Food and Drug Administration. It was reported from Cincinnati.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor
6,668 cases of Breyers Chocolate Truffle Ice Cream across the United States have been recalled by Unilever Manufacturing The affected ice cream cartons actually contain Rocky Road Ice Cream, which contains almonds, a potentially "life-threatening" allergen The U.S. Food and Drug Administration announced the recall on June 10Over 6,600 cases of Breyers Ice Cream have been recalled amid concerns that the product is mislabeled and contains a "life-threatening" allergen. The U.S. Food and Drug Administration confirmed that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 in a Tuesday, June 10 statement. The cause for the recall was determined to be "undeclared allergens and mislabeled product." "Rocky Road Ice was packaged with Chocolate Truffle Ice Cream labeled tub and a Rocky Road Ice Cream lid. Tub said 'may contain tree nuts' the lid said it did contain almonds," the FDA clarified about the recall. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The FDA declared this a Class II recall, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." A representative for Breyers commented on the recall in a statement shared with PEOPLE, saying, "Unilever in the U.S. is voluntarily recalling one lot of Breyers Chocolate Truffle 1.5 quart tubs after some were found to contain Rocky Road ice cream, which includes almonds not listed on the label." The statement continued: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." It is unclear where exactly the cases of ice cream were distributed across the United States. The FDA reported the distribution as targeting "distribution centers and retail locations across the U.S." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Rocky Road is a flavor of ice cream that contains almonds. Although almonds are considered tree nuts, the label for Breyers Chocolate Truffle Ice Cream only says that the product "may contain tree nuts." The Breyers recall comes a few weeks after nearly 18,000 containers of Wells Dairy ice cream and frozen yogurt were recalled due to contamination with hard plastics. Wells Enterprises, which produces Wells Dairy products, was responsible for the recall, which targeted 22 different flavors of frozen desserts. Read the original article on People
Yahoo
an hour ago
- Yahoo
Inspira Technologies says ART100 in use at Tier-1 U.S. hospitals
Inspira Technologies (IINN) announced that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-1 facilities in the U.S. This clinical use reflects growing confidence in the system's potential to support patients in critical condition and positions Inspira at the forefront of a rapidly evolving market of life-saving technologies. The consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities. The Company is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on IINN: Disclaimer & DisclosureReport an Issue Inspira Technologies Boosts ART100 Production Amid European Negotiations Inspira Technologies scales up ART100 production capabilities Inspira Technologies initiated with a Buy at Litchfield Hills Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance Inspira Technologies Launches Global Rollout of ART100 System Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer
SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the F ULF ILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is a patient-centric medical technology company developing a novel approach to treating chronic nociceptive low back pain with the goal of providing durable relief to an underserved patient population. The ULF neuromodulation platform is designed to target localized pain by reducing neuronal responses; suppression of these signals may reduce suffering for patients who have chronic nociceptive low back pain. There are currently no approved SCS treatment options for nociceptive back pain, which presents a $20B market opportunity. 'IDE approval from the FDA represents a significant milestone for Presidio and enables the study of ultra low frequency modulation of the nervous system. The results from our first-in-human clinical trial in Australia, which were presented by Dr. Marc Russo at NANS earlier this year, were very encouraging. We are excited to now begin a more robust trial, which we believe will demonstrate the safety and efficacy of our ULF platform,' said Michael Onuscheck, Presidio Medical's Chief Executive Officer. In addition, the company is pleased to announce Dimas Jiménez has joined as Chief Financial Officer (CFO). Mr. Jiménez brings over four decades of finance experience, spanning roles from Wall Street to both large and start-up life science organizations. He will be responsible for continuing to build the financial infrastructure of Presidio, supporting the commercialization efforts of our ULF neuromodulation system and expanding relationships with current and future investors. 'We are extremely pleased to welcome Dimas to the Presidio team. The breadth and depth of his experience within the life science industry and his expertise in working with pre-commercialization start-up organizations is invaluable as we continue to grow and evolve as a company,' said Onuscheck. 'Presidio's ULF platform has the potential to greatly improve the lives of patients who suffer from debilitating chronic back pain. I've spent a significant amount of my career working with companies whose goal is to disrupt the status quo. I couldn't be more excited to be a part of this mission-driven and patient-centric organization,' said Jiménez. Mr. Jiménez most recently served as the CFO of Spire Health and has held prior positions as CFO at StemoniX and Orphagen Pharmaceuticals. He has managed four company exits and has helped raise $670 million in capital for life science organizations. Mr. Jiménez received a Bachelor of Arts degree from Dartmouth College, a Master of Business Administration from Stanford University and is a Chartered Financial Analyst (CFA). About Presidio Medical Presidio Medical was founded in 2017 and is headquartered in San Mateo, CA. This clinical stage privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity, with a first indication in the treatment of chronic pain. Presidio's investors include Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital. For more information, visit:
